MAPS PBC Announces Positive Topline Results from Long-Term Observational Follow-Up Study on MDMA-Assisted Therapy for Treatment of PTSD

• Interim results show improvements in PTSD symptom severity lasted at least six months after the last treatment session 
• Findings are consistent with previously published Phase 2 data¹ on the sustained effect of MDMA-assisted therapy for the treatment of PTSD

Excerpt from the Press Release:

SAN JOSE, Calif., April 5, 2023 /PRNewswire/ — MAPS Public Benefit Corporation (“MAPS PBC”), a clinical-stage company dedicated to changing the way mental health conditions are treated, announced positive topline results from an observational follow-up study evaluating the long-term safety and efficacy of MDMA-assisted therapy for post–traumatic stress disorder (“PTSD”). Preliminary findings show that participants in this study demonstrated a durable response at least six months, and in some cases a year or more, after their final MDMA-assisted therapy session during the Phase 3 study.

“PTSD is a chronic condition when insufficiently treated and has historically been addressed through long-term maintenance treatment, which is why it’s important to evaluate whether an acute treatment like MDMA-assisted therapy has an enduring response when used to treat PTSD,” said Amy Emerson, chief executive officer, MAPS PBC. “These results are consistent with previously published Phase 2 data demonstrating the sustained effect of MDMA-assisted therapy at least 12 months following treatment and suggest the acute treatment effect could last even longer.”

In the two Phase 3 studies, participants who received therapy with MDMA showed significant improvement over therapy with placebo when measured at two months after the last experimental session, meeting the primary and secondary endpoints.

Click the button below to read the entire Press Release:

Continue Reading The Press Release